17DD and 17D-213/77 Yellow Fever Substrains Trigger a Balanced Cytokine Profile in Primary Vaccinated Children

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Campi Azevedo, Ana Carolina ^a   de Araújo Porto, Luiza Pacheco ^a   Luiza Silva, Maria ^a   Batista, Maurício Azevedo ^b   Martins, Marina Angela ^a   Sathler Avelar, Renato ^a   da Silveira Lemos, Denise ^b   Camacho, Luiz Antonio Bastos ^a   de Menezes Martins, Reinaldo ^c   de Lourdes de Sousa Maia, Maria ^c   Farias, Roberto Henrique Guedes ^c   da Silva Freire, Marcos ^c   Galler, Ricardo ^c   Homma, Akira ^c   Ribeiro, José Geraldo Leite ^d   Lemos, Jandira Aparecida Campos ^d   Auxiliadora Martins, Maria ^e   Caldas, Iramaya Rodrigues ^a   Elói Santos, Silvana Maria ^f   Teixeira Carvalho, Andréa ^a   Martins Filho, Olindo Assis ^a   more..

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^c Instituto de Technologia em Imunobiologicos   (Brazil)

^d Programa de Avaliação e Vigilância   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIBODY; YELLOW FEVER VACCINE; YF 17D 213 77 VACCINE; YF 17DD VACCINE;

ANTIBODY TITER; ARTICLE; BLOOD CULTURE; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IN VITRO STUDY; INFANT; MALE; NORMAL HUMAN; PRIMARY VACCINATION; REFERENCE VALUE; SEROCONVERSION; VACCINATION; VIRUS STRAIN; YELLOW FEVER FLAVIVIRUS;

ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; HUMANS; INFANT; MALE; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 84870920514     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049828     Document Type: Article

References (35)

1. Monath TP, (2005) Yellow fever vaccine. Expert Rev Vaccines 4: 553-574.
2. World Health Organization. Global programme for vaccines and immunization (1998) Expanded programme on immunization. Yellow fever. Geneva. Available: http://www.who.int/vaccines-documents/DocsPDF/www9842.pdf. Accessed 2012 Mar 6.
3. Santos CND, Post PR, Carvalho R, Ferreira II, Rice CM, et al. (1995) Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Vírus Res 35: 35-41.
4. Fleiss JL (1986) The design and analysis of clinical experiments. New York: John Wiley & Sons Inc. DOI: 10.1002/9781118032923.
5. Freestone DS (1994) Yellow fever vaccine. In: Plotkin SA, Mortimer EA, editors. Vaccines 2nd ed. Philadelphia: W.B. Saunders. pp. 741-779.
6. World Health Organization (1998) Requirements for yellow fever vaccine. WHO Tech Rep Ser 872: 31-68.
7. Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, et al. (2002) Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 66: 533-541.
8. Marchevsky RS, da Luz Leal M, Homma A, Coutinho ES, Camacho LA, et al. (2006) Molecular and phenotypic analysis of a working seed lot of yellow fever virus 17DD vaccine strain produced from the secondary seed lot 102/84 with an additional passage in chicken embryos. Biologicals 34: 191-197.
9. Ministério da Saúde (2001) Fundação Nacional de Saúde. Programa Nacional de Imunizações. Manual de Procedimentos para Vacinação. 4a Ed. Brasília: Fundação Nacional de Saúde. Available: http://dtr2001.saude.gov.br/svs/pub/MPV/mpv00.htm. Accessed 2012 Mar 20.
10. World Health Oraganization (2007) Vaccine-preventable diseases and vaccines. In: International Travel and Health. pp. 93-145.
11. Centers for Disease Control and Prevention (2011) In the News Yellow Fever in Brazil: Current Situation. Available: http://wwwnc.cdc.gov/travel/notices/in-the-news/yellow-fever-brazil.htm. Accessed 2012 Feb 26.
12. Camacho LAB, Freire MS, Leal MLF, Aguiar SG, Nascimento JP, et al. (2004) Collaborative Group for the Study of Yellow Fever Vaccines. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saúde Pública 38: 671-678.
13. Belmusto-Worn VE, Sanchez JL, McCarthy K, Nichols R, Bautista CT, et al. (2005) Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow ferver 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 72: 189-197.
14. Collaborative Group for Studies with Yellow Fever Vaccine (2007) Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization. Vaccine 25: 3118-3123.
15. Camacho LA, de Aguiar SG, Freire Mda S, Leal Mda L, do Nascimento JP, et al. (2005) Collaborative Group for the Study of Yellow Fever Vaccines. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial. Rev Saúde Pública 39: 413-420.
16. Stefano I, Sato HK, Pannuti CS, Omoto TM, Mann G, et al. (1999) Recent immunization against measles does not interfere with the seroresponse to yellow fever vaccine. Vaccine 17: 1042-1046.
17. Luiza-Silva M, Campi-Azevedo AC, Batista MA, Martins MA, Avelar RS, et al. (2011) Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody. J Infect Dis 15: 873-883.
18. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, et al. (2006) Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203: 413-424.
19. Martins MA, Silva ML, Elói-Santos SM, Ribeiro JG, Peruhype-Magalhães V, et al. (2008) Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination. Vaccine 26: 1173-1184.
20. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, et al. (2008) Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205: 3119-3131.
21. Santos AP, Matos DC, Bertho AL, Mendonça SC, Marcovistz R, (2008) Detection of Th1/Th2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot assay. Cytokine 42: 152-155.
22. Bae HG, Domingo C, Tenorio A, de Ory F, Muñoz J, et al. (2008) Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis 197: 1577-1584.
23. Silva ML, Espírito-Santo LR, Martins MA, Silveira-Lemos D, Peruhype- Magalhaães V, et al. (2010) Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin Vaccine Immunol 17: 118-126.
24. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, et al. (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10: 116-125.
25. Ahmed R, Pulendran B, Ahmed R, Pulendran B, (2011) Learning vaccinology from viral infections. J Exp Med 208: 2347-2349.
26. Wuthrich M, Filutowicz HI, Warner T, Deepe GS Jr, Klein BS, (2003) Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. J Exp Med 197: 1405-1416.
27. Levitz SM, Golenbock DT, (2012) Beyond Empiricism: Informing Vaccine Development through Innate Immunity Research. Cell 148: 1284-1292.
28. Neves PC, Matos DC, Marcovistz R, Galler R, (2009) TLR expression and NK cell activation after human yellow fever vaccination. Vaccine 27: 5543-5549.
29. Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, et al. (2009) The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 15: 7919-7930.
30. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K, (1981) Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59: 895-900.
31. Meyer HM Jr, Hostetler DD Jr, Bernhein BC, Rogers NG, Lambin P, et al. (1964) Response of Volta children to jet inoculation of combined live measles, smallpox and yellow fever vaccines. Bull World Health Organ 30: 783-794.
32. Robertson SE (1993) The Immunological Basis for Immunization. Module 8: Yellow Fever. Geneva: World Health Organization, WHO/EPI/GEN/93.18. Available: http://www.who.int/vaccines-documents/DocsPDF-IBIe/mod8_e.pdf. Accessed 2012 Apr 4.
33. Georges AJ, Tible F, Meunier DMY, Gonzalez JP, Beraud AM, et al. (1985) Thermostability and efficacy in the field of a new, stabilized yellow fever virus vaccine. Vaccine 3: 313-315.
34. Lhuillier M, Mazzariol MJ, Zadi S, Le Cam N, Bentejac MC, et al. (1989) Study of combined vaccination against yellow fever and measles in infants from six to nine months. J Biol Stand 17: 9-15.
35. Mouchon D, Pignon D, Vicens R, Tu-Ha-Thanh, Tekaia F, et al. (1990) The combined measles-yellow fever vaccination in African infants aged 6 to 10 months. Bull Soc Pathol Exot 83: 537-551.